UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A paracrine requirement for hedgehog signalling in cancer

Nature, 2008-09, Vol.455 (7211), p.406-410

2008

Volltextzugriff (PDF)

A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer

Clinical cancer research, 2013, Vol.19 (1), p.258-267

2013

Volltextzugriff (PDF)

Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

Science (American Association for the Advancement of Science), 2009-10, Vol.326 (5952), p.572-574

2009

Volltextzugriff (PDF)

Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout rats

Toxicology and applied pharmacology, 2023-09, Vol.475, p.116627-116627, Article 116627

2023

Volltextzugriff (PDF)

A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission

Clinical cancer research, 2012-12, Vol.18 (23), p.6509-6518

2012

Volltextzugriff (PDF)

Discovery and development of DNA methylation-based biomarkers for lung cancer

Epigenomics, 2014-02, Vol.6 (1), p.59-72

2014

Volltextzugriff (PDF)

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Clinical cancer research, 2014-09, Vol.20 (17), p.4488-4498

2014

Volltextzugriff (PDF)

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence

Cancer discovery, 2011-12, Vol.1 (7), p.573-579

2011

Volltextzugriff (PDF)

Discovery and preclinical development of vismodegib

Expert opinion on drug discovery, 2014-08, Vol.9 (8), p.969-984

2014

Volltextzugriff (PDF)

Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened

Clinical cancer research, 2011-05, Vol.17 (10), p.3378-3387

2011

Volltextzugriff (PDF)

HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors

Molecular cancer therapeutics, 2013-06, Vol.12 (6), p.1122-1130

2013

Volltextzugriff (PDF)

Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading

Nature medicine, 1997-10, Vol.3 (10), p.1133-1136

1997

Volltextzugriff (PDF)

Direct Extracellular Contact between Integrin α3β1 and TM4SF Protein CD151

The Journal of biological chemistry, 2000-03, Vol.275 (13), p.9230-9238

2000

Volltextzugriff (PDF)

Preferential Induction of IL-10 in APC Correlates with a Switch from Th1 to Th2 Response Following Infection with a Low Pathogenic Variant of Theiler's Virus

The Journal of immunology (1950), 2002-04, Vol.168 (8), p.4221-4230

2002

Volltextzugriff (PDF)

Abstract 5869: Characterization and therapeutic implications of SMARCA4 mutations in cancer

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5869-5869

2020

Volltextzugriff (PDF)

Potential Role of CD4+ T Cell-Mediated Apoptosis of Activated Astrocytes in Theiler's Virus-Induced Demyelination

The Journal of immunology (1950), 1999-06, Vol.162 (11), p.6543-6551

1999

Volltextzugriff (PDF)

Role of Individual T-Cell Epitopes of Theiler’s Virus in the Pathogenesis of Demyelination Correlates with the Ability To Induce a Th1 Response

Journal of Virology, 1998-07, Vol.72 (7), p.6169-6174

1998

Volltextzugriff (PDF)

Abstract 3602: Cross-resistance to 1st, 2nd, and 3rd generation EGFR tyrosine kinase inhibitors in vitro is characterized by MET amplification and PTEN loss

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3602-3602

2015

Volltextzugriff (PDF)

Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase

Biochemical journal, 2000-11, Vol.351 Pt 3 (3), p.629-637

2000

Volltextzugriff (PDF)

Abstract 2790: PRC2 mediated repression of SMARCA2 predicts for EZH2 inhibitor activity in tumors with SWI/SNF mutations

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2790-2790

2017

Volltextzugriff (PDF)

Reproducible pharmacogenomics profiling of cancer cell line panels

Nature (London), 2016-05, p.333

2016

Volltextzugriff (PDF)

Abstract 5559: Exploratory analysis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) PIK3CA mutated (mut) advanced breast cancer (aBC) treated with taselisib (TAS) and/or fulvestrant (FUL) reveals increased CCNE2 expression with poor outcome to placebo (PBO) + FUL but not TAS + FUL in SANDPIPER

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5559-5559

2023

Volltextzugriff (PDF)

Highly Stoichiometric, Stable, and Specific Association of Integrin α3β1 with CD151 Provides a Major Link to Phosphatidylinositol 4-Kinase, and May Regulate Cell Migration

Molecular biology of the cell, 1998-10, Vol.9 (10), p.2751-2765

1998

Volltextzugriff (PDF)

26 – 50 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(71)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(41)
Humans
(39)
Animals
(22)
Oncology
(19)
Biological And Medical Sciences
(17)
Female
(17)
Mice
(17)
Medical Sciences
(16)
Mutation
(15)
Tumors
(14)
Cell Line, Tumor
(11)
Adult
(10)
Cancer
(10)
Male
(10)
Antineoplastic Agents
(9)
Pharmacology. Drug Treatments
(9)
Signal Transduction - Drug Effects
(9)
Amino Acid Sequence
(8)
Antineoplastic Agents - Therapeutic Use
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A paracrine requirement for hedgehog signalling in cancer

A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer

Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout rats

A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission

Correction: High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

Discovery and development of DNA methylation-based biomarkers for lung cancer

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence

Discovery and preclinical development of vismodegib

Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened

HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors

Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading

Direct Extracellular Contact between Integrin α3β1 and TM4SF Protein CD151

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

Preferential Induction of IL-10 in APC Correlates with a Switch from Th1 to Th2 Response Following Infection with a Low Pathogenic Variant of Theiler's Virus

Abstract 5869: Characterization and therapeutic implications of SMARCA4 mutations in cancer

Potential Role of CD4+ T Cell-Mediated Apoptosis of Activated Astrocytes in Theiler's Virus-Induced Demyelination

Role of Individual T-Cell Epitopes of Theiler’s Virus in the Pathogenesis of Demyelination Correlates with the Ability To Induce a Th1 Response

Abstract 3602: Cross-resistance to 1st, 2nd, and 3rd generation EGFR tyrosine kinase inhibitors in vitro is characterized by MET amplification and PTEN loss

Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase

Abstract 2790: PRC2 mediated repression of SMARCA2 predicts for EZH2 inhibitor activity in tumors with SWI/SNF mutations

Reproducible pharmacogenomics profiling of cancer cell line panels

Highly Stoichiometric, Stable, and Specific Association of Integrin α3β1 with CD151 Provides a Major Link to Phosphatidylinositol 4-Kinase, and May Regulate Cell Migration

Suchergebnisse filtern